Navigation Links
Arpida Annual General Meeting of Shareholders Approves All Board Proposals
Date:5/7/2009

REINACH, Switzerland, May 7 /PRNewswire-FirstCall/ -- The Annual General Meeting of Arpida Ltd (SIX: ARPN) has approved the proposals that were put forward by the Board of Directors.

A total of 90 shareholders were present at the meeting that took place in Reinach today. 4,629,711 shares were represented, or 21.9% of the total number of shares issued (21,094,104).

The following items were on the agenda.

1. Information on strategic options

There was a lively discussion regarding the possible strategic scenarios as presented by the CEO, Dr Jurgen Raths. An overview of these scenarios was already published in a press release earlier today. Shareholders provided valuable comments that will be incorporated in the further strategic evaluation. No decision was taken yet. The Board of Directors assured the shareholders that they will be duly involved in any major strategic decision.

2. Approval of the 2008 Business Report, Company Accounts and Group Accounts

The shareholders approved the 2008 Business Report, comprising the annual financial statements, the consolidated accounts and the 2008 Annual Report.

3. Discharge of the Board of Directors and of the Senior Executive Officers

The shareholders granted discharge to the Board of Directors and to the Senior Executive Officers for their actions.

4. Compensation of Losses with General Reserves

The shareholders approved the Board proposal to compensate the accumulated loss of CHF 189,591,477 with an equal amount of share premium in the general reserves.

5. Re-election of the Auditors

The shareholders re-elected PricewaterhouseCoopers Ltd as Auditors for 2009.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

    Contacts:
    Dr Jurgen Raths, President and CEO
    Tel.: +41-61-417-96-60

    Harry Welten, MBA, CFO and Senior Vice President
    Tel.: +41-61-417-96-65

    Paul Verbraeken, Head of Corporate Communications
    Tel.: +41-61-417-96-83



'/>"/>
SOURCE Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... Wendelsheim, Germany (PRWEB) , ... June 22, 2017 ... ... , is taking over the allergy specialists DST Diagnostische Systeme & Technologien GmbH, ... We all know someone who suffers from hay fever, urticaria, asthma, atopic eczema ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... the release of Limfinity® version 6.5, a content-packed update to the Limfinity® framework. ... gain a larger and more diverse base of customers among labs and other ...
(Date:6/20/2017)...  Kibow Biotech Inc., a pioneer in developing "Enteric ... a new patent covering a unique method for preventing ... and Trademark Office on May 23 rd 2017. ... Bio award in 2014 in San Diego, ... to chronic disease. Renadylâ„¢, the first and only dietary ...
(Date:6/19/2017)... NJ (PRWEB) , ... June 19, 2017 , ... ... innovative solutions for clinical development reported today that it is launching two new ... The company will be demonstrating new capabilities at the DIA 2017 Annual Meeting ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
Breaking Biology News(10 mins):